{
  "id": "5e2dbc55fbd6abf43b000016",
  "type": "factoid",
  "question": "What has pimavanserin been approved for by the FDA (2018)?",
  "ideal_answer": "Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28493654"
  ],
  "snippets": [
    {
      "text": "To summarize the US Food and Drug Administration's (FDA's) review of the safety and effectiveness for pimavanserin, an atypical antipsychotic, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin is the only FDA-approved treatment for the hallucinations and delusions seen in patients with psychosis of Parkinson's disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "hallucinations and delusions associated with Parkinson's disease psychosis"
}